RenovoRX
  • Media
  • Careers
  • Investors
  • About
    • Leadership Team
    • Board of Directors
    • Advisory Board
  • Clinical Trials
    • About TIGeR-PaC
    • TIGeR-PaC
      Candidate Criteria
    • TIGeR-PaC Participating
      Clinical Sites
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • Contact
  • About
    • Leadership Team
    • Board of Directors
    • Advisory Board
  • Clinical Trials
    • About TIGeR-PaC
    • TIGeR-PaC
      Candidate Criteria
    • TIGeR-PaC Participating
      Clinical Sites
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • News
  • Careers
  • Investors
  • Contact
Investors

Investors

  • Overview
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • News & Events
    • Overview
    • Press Releases
    • Clinical News
    • IR Calendar Events
    • Email Alerts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Clinical News
  • IR Calendar Events
  • Email Alerts
May 01, 2023 8:30am EDT

RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event

Apr 28, 2023 8:30am EDT

RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023

Apr 27, 2023 8:30am EDT

RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

Apr 14, 2023 8:30am EDT

RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida

Apr 11, 2023 8:30am EDT

RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

Mar 30, 2023 12:20pm EDT

RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Mar 30, 2023 8:30am EDT

RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

Mar 08, 2023 8:30am EST

RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGem™ as a Treatment Option for Locally Advanced Pancreatic Cancer

Mar 02, 2023 8:30am EST

RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone

Mar 01, 2023 8:30am EST

RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

4546 El Camino Real, Suite B1
Los Altos, CA 94022

(650) 284-4433

(650) 397-4433

RenovoRX

Delivering Therapy Where it Matters

Quicklinks
  • About
  • Clinical Trials
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • Media
  • Careers
  • Investors
  • Contact

Delivering Therapy Where it Matters

4546 El Camino Real, Suite B1
Los Altos, CA 94022

(650) 284-4433

(650) 397-4433

Quicklinks
  • About
  • Clinical Trials
  • Our Therapy Platform
  • Pipeline Overview
  • Clinicians
  • News
  • Careers
  • Investors
  • Contact

© Copyright 2018-2023 RenovoRx®. All rights reserved. Site by Sheriar Designs.

Privacy Statement | Terms of Use

Menu